Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02527434
Title Study of Tremelimumab in Patients With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

Advanced Solid Tumor

Therapies

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.